Comparative Pharmacology
Head-to-head clinical analysis: TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE versus ZUPLENZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE versus ZUPLENZ.
TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE vs ZUPLENZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Trimethobenzamide is a centrally acting antiemetic that inhibits the chemoreceptor trigger zone (CTZ) in the medulla oblongata by suppressing emetic stimuli. Its exact mechanism is not fully understood but may involve antagonism of dopamine D2 receptors and possibly serotonin 5-HT3 receptors.
Competitive serotonin 5-HT3 receptor antagonist; acts centrally on the chemoreceptor trigger zone and peripherally on GI vagal nerve terminals to inhibit emesis.
300 mg orally or intramuscularly 3 to 4 times daily as needed for nausea and vomiting.
8 mg administered intraorally as a single dose 1 hour before chemotherapy; may repeat once if vomiting occurs within 30 minutes after initial dose.
None Documented
None Documented
Terminal elimination half-life approximately 7-9 hours in adults; prolonged in renal impairment (up to 20-30 hours).
Terminal elimination half-life 3.5 hours; in hepatic impairment increases to 7-9 hours
Primarily renal (50-70% as unchanged drug and metabolites) and biliary (~20-30%); less than 5% fecal.
Renal 70% unchanged, fecal 20% (including biliary metabolites), 10% metabolized
Category C
Category C
Antiemetic
Antiemetic